Compare MKS Instruments (MKSI) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MKS Instruments vs Vertex Pharmaceuticals Incorporated — how do they compare? MKS Instruments trades at $268.04 (market cap $17.95B), while Vertex Pharmaceuticals Incorporated trades at $521.58 (market cap $134.06B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 7.5× MKS Instruments's market cap, and MKS Instruments pays a 0.38% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| MKSI | VRTX | |
|---|---|---|
Market Cap | $17.95B | $134.06B |
Sector | Technology | Health |
52-Week High | $444.80 | $557.96 |
52-Week Low | $110.60 | $376.62 |
Enterprise Value | $21.53B | $128.18B |
Dividend Yield | 0.38% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, with a bullish technical signal and strong fundamentals. The stock shows robust profitability with an 86% gross margin and 35% net margin, supported by $12.0B revenue in 2025. Recent acquisition of Crinetics Pharmaceuticals expands its pipeline, while analyst consensus remains strongly bullish with an 85.7% buy rating and a $548.78 price target.
Outlook is positive driven by revenue growth and pipeline expansion, but risks include clinical setbacks and competition. The stock offers upside to the consensus target, with cash flow recovery in 2025 signaling operational strength. Investors should weigh high valuation multiples against earnings consistency and market sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MKS Instruments
MKS develops instruments, systems, and process control solutions for advanced manufacturing. Its technologies serve semiconductor manufacturing, electronics and packaging, photonics, and specialty industrial applications.
Read more on MKSI →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
